Biganib 90 mg (Brigatinib) Tablets


Biganib 90 mg (Brigatinib) Tablets


Biganib 90 mg, containing Brigatinib and manufactured by Drug International Limited, signifies a significant advancement in the treatment of non-small cell lung cancer (NSCLC). As a globally renowned distributor of oncology-based products, Orio Pharma plays a pivotal role in disseminating crucial information about Biganib to healthcare providers and patients worldwide.

Description and Usage:

Biganib90 mg, featuring Brigatinib as its active ingredient, is a potent and selective inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) mutations, commonly associated with NSCLC. This medication is specifically indicated for the treatment of patients with metastatic ALK-positive NSCLC who have progressed on or are intolerant to crizotinib. Brigatinib exerts its therapeutic effects by inhibiting ALK and EGFR tyrosine kinases, thereby impeding cancer cell proliferation and survival. Administered orally, Biganib offers a convenient treatment option for individuals with advanced NSCLC.

Clinical Applications:

Clinical trials have demonstrated the efficacy of Biganib in eliciting durable responses and enhancing progression-free survival in patients with ALK-positive NSCLC. Its capacity to penetrate the blood-brain barrier and effectively target central nervous system (CNS) metastases further amplifies its utility in the management of advanced NSCLC. Biganib emerges as a valuable therapeutic choice for patients who have experienced disease progression on prior ALK inhibitors or necessitate CNS activity.

Adverse Effects and Safety Profile:

The common adverse effects associated with Biganib include nausea, diarrhea, fatigue, cough, and headache. However, serious adverse events such as interstitial lung disease, hypertension, and bradycardia may occur, necessitating vigilant monitoring during treatment. Patient education and regular monitoring by healthcare providers are imperative to mitigate risks and optimize treatment outcomes.


In conclusion, Biganib 90 mg stands as a significant innovation in the management of ALK-positive NSCLC, offering patients a targeted therapy with the potential for durable responses and enhanced progression-free survival. The collaboration between Drug International Limited and Orio Pharma underscores a shared commitment to advancing patient care in oncology. Through strategic distribution and comprehensive support services, Biganib holds promise in making a substantial impact on the lives of individuals affected by advanced NSCLC.

Manufacturer and Supplier Information:

Drug International Limited, the esteemed manufacturer of Biganib, upholds stringent quality standards and innovation in pharmaceutical manufacturing. Orio Pharma serves as the global distributor, ensuring efficient access to Biganib for patients and healthcare providers worldwide.

Oncology Information Provider Section:

Orio Pharma serves as a trusted source of information for oncologists, pulmonologists, and healthcare providers involved in the management of NSCLC. Through educational initiatives, clinical resources, and patient support programs, Orio Pharma empowers stakeholders with the knowledge and tools needed to optimize patient care and improve treatment outcomes in oncology.

Clinical Research:

Ongoing clinical research endeavors aim to explore the potential applications of Biganib in other ALK-driven malignancies and evaluate its efficacy in combination with other targeted agents or immunotherapies. These efforts seek to further elucidate Biganib’s role in cancer therapy and expand treatment options for patients with ALK-positive tumors.

Patient-Centric Support Programs:

In addition to its therapeutic benefits, Biganib 90 mg prioritizes patient-centered care through comprehensive support programs. Orio Pharma offers a range of patient support services, including access to financial assistance programs, medication adherence support, and psychosocial resources. These programs aim to address the diverse needs of patients and caregivers, ensuring that individuals undergoing Biganib therapy receive holistic support to navigate their cancer journey with resilience and confidence.

Global Access and Affordability:

Orio Pharma is committed to ensuring equitable access to Biganib 90 mg worldwide. Through partnerships with healthcare organizations and advocacy for fair pricing policies, Orio Pharma strives to make Biganib accessible to patients across diverse socioeconomic backgrounds and geographic regions. By addressing barriers to access and advocating for patient-centric healthcare policies, Orio Pharma supports the principle of universal healthcare coverage and promotes equity in cancer care delivery.